We plan to investigate the molecular mechanism underlying the increased plasma LCN2 levels in patients with MOG-IgG–positive optic neuritis with a focus on clinical factors that may influence plasma LCN2 levels in patients with MOG-IgG associated disorders. This evidence concerns the gene MOG and optic neuritis.